BE COMPLETE RCT Bimekizumab vs. PBO in TNFiIR PsA pts meets its primary criteria at 16wks w/ -ACR50 43% -PASI 90 69% and MDA achieved in 40+% pts No new safety signal. @RheumNow #EULAR2022 OP0255 https://t.co/QazYlzDqIc

Real world study of over 6500 patients from a French Health Insurance database by Pina Vegas et al showed higher persistence of IL17i than TNFi for PsA and PsO. IL17i had better persistence than IL12/23 for PsA and no difference for PsO over 3 years #EULAR2022 @RheumNow POS0075 https://t.co/hBI8tgb5Jb

No significant difference in malignancy risk in patients with rheumatic disease and a prior history of malignancy, who started bDMARDs or tsDMARDs. Interestingly IL-17i had 0 malignancy events and CD-20i were next lowest. @RheumNow #EULAR2022 ABST#OP0138 https://t.co/Mq3YvOrSY8

Large French study of over 23k patients with either PsA or PsO showed a longer persistence (time of initiation to discontinuation) in those who took IL-17i vs. TNFi for PsA and PsO pts. IL-17i longer than IL-12/23i in PsA pts. @RheumNow #EULAR2022 ABST#POS0075 https://t.co/rH1g4fPUYC

#EULAR2022 ASAS/EULAR AxSpA Recs ⭐️Last: 2016 ▶️All: education, exercise, 🚭 ▶️❌csDMARD for axial disease ▶️TNF/IL17 (or JAK) with high disease: ASDAS>/=2.1 ▶️Monoclonal TNF for uveitis/IBD, high PsO: IL-17 ▶️Sustained remission: tapering of bDMARD "can be considered" @RheumNow https://t.co/3yYU0Vb37r

Do biomarkers correlate with change in disease activity in #PsA? Esp IL17F not so much other IL17s, and IL6, IL23. Ian McInnes ? next steps 🤷‍♀️ to separate responder and non responder @RheumNow #EULAR2022 OP0024 https://t.co/JMmENRa80t